演題抄録

FACO/JSCO Joint Symposium

開催概要
開催回
第54回・2016年・横浜
 

FACO における最初の国際共同臨床試験- CONVOGC-1の現状

演題番号 : FAJS-1

[筆頭演者]
吉田 和弘:1 

1:岐阜大学・腫瘍外科学(第2外科)

 

FACO was founded on 11 Feb 2012 as an organization of Clinical Oncology in Asia with collaboration with Japan, Korea and China. One of its man roles is to perform clinical trials and translation research to develop gold standard therapies and cancer care in Asia. As a candidate for initial clinical trial was decided to perform on gastric cancer on 26 Sept 2013.
The first FACO clinical Trial, CONVO-GC-1 has been successfully started its patient enrollment from First of April, 2016. Generally, conversion therapy can be defined as a surgical treatment aiming at an R0 resection after chemotherapy, for tumors that were originally technically and/or oncologically unresectable or marginally resectable. We have proposed new categories of classification of stage IV gastric cancer standing on the biology of the tumors and treatment strategy for the patients. Stage IV GC patients can be divided based on the absence (categories 1 and 2) or presence (category 3 and 4) of macroscopically detectable peritoneal dissemination. Category 1 is defined oncologically as stage IV but the metastasis is technically resectable. Category 2 includes a marginally resectable metastasis or patients for whom the operation would not necessarily be the best the choice. Category 3 includes a potentially unresectable metastasis of peritoneal dissemination that is only macroscopically detectable. Category 4 includes non-curable metastasis with peritoneal and other organ metastasis. The indications for conversion therapy might include the patients from category 2, some patients from category 3 and very small number of patients from category 4. The provision of conversion therapy for stage IV GC patients might be one of the main roles of surgical oncologists in the near future and the FACO first trial will collect the basic data among Asian countries.

前へ戻る